Avelumab and Merkel Cell Carcinoma: A Clinical Evidence Review on Causation

From General Health Science to Occupational Exposure Concerns

General health and science communication has long served as a bridge between complex biomedical research and public understanding, distilling large-scale clinical evidence into actionable insights. For decades, this legacy has focused on broad population-level interventions—such as the recent large-scale Japanese trial examining low-dose aspirin’s effect on cardiovascular outcomes in older adults with common risk factors. Such studies exemplify how rigorous evidence review informs preventive strategies, emphasizing safety and efficacy across diverse cohorts. Transitioning from this general health context to a more targeted occupational exposure concern requires a shift in focus from population-wide prevention to specific environmental or pharmaceutical exposures. In occupational settings, workers may encounter substances that, while beneficial in controlled therapeutic contexts, pose distinct risks under chronic or high-level exposure conditions. This pivot necessitates examining how clinical evidence frameworks—originally designed for broad public health questions—can be adapted to assess causation in narrower, exposure-driven scenarios.

Bridging to Avelumab and Merkel Cell Carcinoma

Consider the case of avelumab, a therapeutic monoclonal antibody used in oncology, and its association with Merkel cell carcinoma. While avelumab is administered in clinical settings, its potential role in carcinogenesis raises questions relevant to occupational health, particularly for healthcare workers or researchers handling biologics. The transition from general health literacy to occupational exposure concern thus involves applying the same rigorous evidence review standards to evaluate whether avelumab exposure—beyond its intended therapeutic use—may contribute to Merkel cell carcinoma risk. This reframing preserves academic neutrality while narrowing the analytical lens.

Clinical Evidence on Avelumab and Merkel Cell Carcinoma

Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It has been approved in the United States, the European Union, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with a poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/29799096/). This approval was based on the two-part, single-arm, phase II JAVELIN Merkel 200 trial, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). Avelumab is thus the first therapeutic agent specifically approved for this indication and is approved independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/). Merkel cell carcinoma is a highly aggressive skin cancer with neuroendocrine differentiation, and its incidence is increasing (https://pubmed.ncbi.nlm.nih.gov/35877101/). The disease is associated with chronic exposure to ultraviolet light and the Merkel cell polyoma virus (https://pubmed.ncbi.nlm.nih.gov/35877101/). Despite advances in systemic therapy, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors (ICIs) progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). For patients who become refractory to avelumab, efficient and safe treatment options are lacking (https://pubmed.ncbi.nlm.nih.gov/33439294/). In a multicenter study of the prospective skin cancer registry ADOREG, response rates to PD-1/PD-L1 inhibition in metastatic MCC were reported to be up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). However, in avelumab-refractory patients, subsequent treatment with combined ipilimumab and nivolumab has shown activity, with three out of five patients in one study responding according to RECIST 1.1 criteria (https://pubmed.ncbi.nlm.nih.gov/33439294/).

Mechanistic Pathways and Risk Context

The mechanistic pathway linking avelumab to MCC is primarily therapeutic, as the drug is designed to treat the disease by blocking PD-L1 and thereby enhancing the immune system's ability to attack cancer cells. However, avelumab is known to cause overactivation of the immune system, leading to immune-related adverse events (irAEs) (https://pubmed.ncbi.nlm.nih.gov/31543781/). One reported case describes hypercalcemia secondary to reactivation of sarcoidosis in a patient with metastatic MCC on avelumab; the hypercalcemia was managed with corticosteroids to full resolution, and avelumab therapy was safely continued (https://pubmed.ncbi.nlm.nih.gov/31543781/). This case illustrates that while avelumab is effective against MCC, it can also trigger immune-mediated complications that require careful management. Regarding risk considerations, the adequacy of warnings about avelumab and MCC must be evaluated in the context of its approved use. The drug's prescribing information includes warnings about immune-related adverse events, which are common to the class of checkpoint inhibitors. However, the specific risk of avelumab causing or exacerbating MCC is not a concern, as the drug is indicated for treatment of the disease. Instead, the primary risk is that avelumab may not be effective for all patients, with approximately 50% progressing on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). For affected patients, causation-related considerations involve understanding that avelumab is a treatment for MCC, not a cause of the disease. The timeline between exposure to avelumab and documented harm typically involves the development of immune-related adverse events, which can occur weeks to months after initiation of therapy, as seen in the case of sarcoidosis reactivation (https://pubmed.ncbi.nlm.nih.gov/31543781/). Additionally, for patients who are refractory to avelumab, the timeline to progression may be variable, and subsequent treatment options such as ipilimumab plus nivolumab may be considered (https://pubmed.ncbi.nlm.nih.gov/33439294/). In summary, avelumab is an established treatment for metastatic MCC, with a mechanism of action that targets PD-L1 to enhance anti-tumor immunity. While it is not a cause of MCC, it can induce immune-related adverse events that require monitoring and management. The evidence supports its efficacy in a subset of patients, but also highlights the need for alternative therapies for those who become refractory.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is avelumab and how is it used in Merkel cell carcinoma?

Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody that targets PD-L1, functioning as an immune checkpoint inhibitor. It is approved for the treatment of metastatic Merkel cell carcinoma (MCC) based on the JAVELIN Merkel 200 trial, which showed objective responses in about one-third of chemotherapy-refractory patients (https://pubmed.ncbi.nlm.nih.gov/29799096/).

Can avelumab cause Merkel cell carcinoma?

No, avelumab is a treatment for Merkel cell carcinoma, not a cause. The drug is designed to treat MCC by enhancing the immune response against cancer cells. However, it can cause immune-related adverse events such as sarcoidosis reactivation (https://pubmed.ncbi.nlm.nih.gov/31543781/).

What are the risks associated with avelumab therapy?

The primary risks include immune-related adverse events (irAEs) common to checkpoint inhibitors, such as hypercalcemia from sarcoidosis reactivation (https://pubmed.ncbi.nlm.nih.gov/31543781/). Additionally, about 50% of patients may progress on therapy, requiring alternative treatments (https://pubmed.ncbi.nlm.nih.gov/35877101/).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.